trending Market Intelligence /marketintelligence/en/news-insights/trending/Buc9he6C3c-HEDM45SuaQA2 content esgSubNav
In This List

Ziopharm Oncology names president

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Ziopharm Oncology names president

ZIOPHARM Oncology Inc. said David Mauney has been promoted to president, effective Dec. 13.

Mauney joined the company in 2017 as executive vice president and chief business officer. Previously, Mauney served as managing director at Harvest Capital Strategies LLC.

Boston-based Ziopharm Oncology is a biotechnology company that focuses on acquiring, developing and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens.